NEW YORK--(BUSINESS WIRE)--Allara, the first comprehensive care platform to support and empower the one in ten women with Polycystic Ovary Syndrome (PCOS), today announced the launch of their hormonal Diagnostic Tool. The test is designed to uncover and address a set of hormonal and metabolic markers, providing clarity around a range of symptoms - from physical symptoms like weight gain and acne to “invisible” symptoms like fatigue and anxiety.
For an early access rate of $149, patients will experience an advanced hormonal and metabolic diagnostic test, which will then be reviewed during a 30-minute, in-depth video consultation with an Allara medical provider to comprehensively analyze the results and help each individual navigate the next steps on their treatment plan. They will also receive nutritional resources to achieve hormonal balance, materials to better understand symptoms, and access to a private community of Allara members to support their journey.
“Women deserve answers, to feel good in their bodies, and to live a life not dictated by constantly feeling unwell,” said Rachel Blank, Founder and CEO of Allara. “That’s why we launched our new Diagnostic Tool. Whether women discover they have PCOS or their results reveal another condition, we are here to unpack their results and point them in the right direction to receive the holistic care they deserve.”
The diagnostic tool measures several factors to determine next steps: Allara tests for LSH, FH, Testosterone, AMH, thyroid levels, and more, to determine potential hormonal imbalances and conditions like PCOS. Additionally, the test analyzes metabolic factors including insulin resistance, cholesterol levels, vitamin deficiencies, and inflammation levels.
On average, it takes women over three years and multiple doctors visits to get a PCOS diagnosis, with 50% of women who have PCOS going undiagnosed. Not only can Allara reduce the time to diagnose PCOS from years to days, it can also help identify other possible hormonal conditions and flag comorbidities women with the reproductive disease are at increased risk of, including type-2 diabetes, high cholesterol, and vitamin deficiencies.
“PCOS is a disorder that doesn't manifest the same way for each person. PCOS varies across women and, even for the same woman, can bring different challenges at different points in the life course,” said Dr. Heather Huddleston, director of the PCOS clinic at UCSF and an Allara Medical Advisor. “Women deserve to have the most comprehensive and current assessment of their health possible. Allara's tool can help women understand how PCOS is impacting them, both hormonally and metabolically, and can provide guidance on best management techniques. I love that Allara is empowering women with the key information they need to understand PCOS in their own personal context.”
Allara is partnering with Bioreference for its lab testing services so that women can get their blood tested in the convenience of their home through Bioreference’s at-home phlebotomy services.
Since its launch last June, Allara has seen huge growth. Currently, the PCOS treatment platform has a waiting list of over 10,000 women seeking care. Allara is currently available in eleven states including: CA, TX, FL, NY, MD, VA, PA, GA, IL, CT and MA, with plans to expand to all 50 by the end of 2022.
To learn more and enjoy early access, please visit: https://try.allarahealth.com/diagnostic-2/.
About Allara:
Allara is the first chronic care platform for women with Polycystic Ovary Syndrome (PCOS), making expert-led, holistic healthcare accessible online. PCOS is one of the world’s most common hormonal disorders, affecting 1 in 10 women of reproductive age—and yet, far too many women lack the care, support, and answers they need to effectively manage their symptoms. Allara is here to change that.
